Only in Titles

           Search results for: CD47   

paperclip

#29342112   // Save this To Up

Useful Bicistronic Reporter System for Studying Poly(A) Site-Defining cis Elements and Regulation of Alternative Polyadenylation.

The link between polyadenylation (pA) and various biological, behavioral, and pathological events of eukaryotes underlines the need to develop in vivo polyadenylation assay methods for characterization of the cis-acting elements, trans-acting factors and environmental stimuli that affect polyadenylation efficiency and/or relative usage of two alternative polyadenylation (APA) sites. The current protein-based CAT or luciferase reporter systems can measure the polyadenylation efficiency of a single pA site or candidate cis element but not the choice of two APA sites. To address this issue, we developed a set of four new bicistronic reporter vectors that harbor either two luciferase or fluorescence protein open reading frames connected with one Internal Ribosome Entry Site (IRES). Transfection of single or dual insertion constructs of these vectors into mammalian cells demonstrated that they could be utilized not only to quantify the strength of a single candidate pA site or cis element, but also to accurately measure the relative usage of two APA sites at both the mRNA (qRT-PCR) and protein levels. This represents the first reporter system that can study polyadenylation efficiency of a single pA site or element and regulation of two APA sites at both the mRNA and protein levels.

1988 related Products with: Useful Bicistronic Reporter System for Studying Poly(A) Site-Defining cis Elements and Regulation of Alternative Polyadenylation.

pCAMBIA0305.1 Vector, (Gu pCAMBIA0380 Vector (No Re pCAMBIA0390 Vector (No Re pCAMBIA1200 Vector (No Re pCAMBIA1300 Vector (No Re pCAMBIA1380 Vector (No Re pCAMBIA1390 Vector (No Re pCAMBIA2200 Vector (No Re pCAMBIA2300 Vector (No Re Cellufine Formyl , 50 ml Cellufine Formyl Media Cellufine Formyl , 500 ml

Related Pathways

paperclip

#29338788   // Save this To Up

High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sources.

Mesenchymal stromal cells (MSC) are a heterogeneous population of multipotent progenitors used in the clinic because of their immunomodulatory properties and their ability to differentiate into multiple mesodermal lineages. Although bone marrow (BM) remains the most common MSC source, cord blood (CB) can be collected noninvasively and without major ethical concerns. Comparative studies comprehensively characterizing the MSC phenotype across several tissue sources are still lacking. This study provides a 246-antigen immunophenotypic analysis of BM- and CB-derived MSC aimed at identifying common and strongly expressed MSC markers as well as the existence of discriminating markers between the two sources.

1273 related Products with: High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sources.

MarkerGeneTM Gaussia Luci Alkaline Phospatase (ALP) Bovine Androstenedione,AS MarkerGene™ â Galactos MarkerGene™ Cellular Se Astra Blue 6GLL, Stain fo MarkerGene™ Multiple Dr Rat monoclonal anti mouse Angiotensin-Converting En Angiotensin Converting En Angiotensin-Converting En Angiotensin Converting En

Related Pathways

paperclip

#29336991   // Save this To Up

SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.

Inhibitory immune checkpoint blockade has been one of the most significant advances in anticancer therapy of the past decade. Research so far has largely focused on improving adaptive immune functions, but recent studies have indicated that the signal-regulatory protein (SIRP)α-CD47 pathway, a phagocytosis checkpoint in macrophages and other innate immune cells, may be an interesting therapeutic target. Here, we summarize current knowledge about SIRPα-CD47 blockade, and highlight key issues for future investigations. These include the targeting of prophagocytic receptors (Fc receptors or otherwise) to complement SIRPα-CD47 blockade, the understanding of constraints on phagocytosis other than the SIRPα-CD47 checkpoint and the contribution of immune cells other than macrophages. A better understanding of how SIRPα-CD47 blockade works may aid in identifying patients suitable for this therapy, avoiding potential toxicities and designing optimal combination therapies.

2561 related Products with: SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.

Interleukin-34 IL34 (N-t Interleukin-34 IL34 anti Sterile filtered goat se Sterile filtered goat se Sterile filtered mouse s Sterile filtered rat ser ING1B antisense ING1B sense Interferon γ p19 INK4D AKT1 (dn) Inducible Insulin

Related Pathways

paperclip

#29333661   // Save this To Up

Nanocage-Therapeutics Prevailing Phagocytosis and Immunogenic Cell Death Awakens Immunity against Cancer.

A growing appreciation of the relationship between the immune system and the tumorigenesis has led to the development of strategies aimed at "re-editing" the immune system to kill tumors. Here, a novel tactic is reported for overcoming the activation-energy threshold of the immunosuppressive tumor microenvironment and mediating the delivery and presentation of tumor neoantigens to the host's immune system. This nature-derived nanocage not only efficiently presents ligands that enhance cancer cell phagocytosis, but also delivers drugs that induce immunogenic cancer cell death. The designed nanocage-therapeutics induce the release of neoantigens and danger signals in dying tumor cells, and leads to enhancement of tumor cell phagocytosis and cross-priming of tumor specific T cells by neoantigen peptide-loaded antigen-presenting cells. Potent inhibition of tumor growth and complete eradication of tumors is observed through systemic tumor-specific T cell responses in tumor draining lymph nodes and the spleen and further, infiltration of CD8+ T cells into the tumor site. Remarkably, after removal of the primary tumor, all mice treated with this nanocage-therapeutics are protected against subsequent challenge with the same tumor cells, suggesting development of lasting, tumor-specific responses. This designed nanocage-therapeutics "awakens" the host's immune system and provokes a durable systemic immune response against cancer.

1391 related Products with: Nanocage-Therapeutics Prevailing Phagocytosis and Immunogenic Cell Death Awakens Immunity against Cancer.

Rabbit Anti-Cell death in Rabbit Anti-Cell death in Rabbit Anti-Cell death in Rabbit Anti-Cell death in Rabbit Anti-Cell death in Rabbit Anti-Cell death in Rabbit Anti-Cell death in Rabbit Anti-Cell death in Rabbit Anti-Cell death in Rabbit Anti-Cell death in Rabbit Anti-Cell death in Rabbit Anti-Cell death in

Related Pathways

  •  
  • No related Items
paperclip

#29321087   // Save this To Up

CD47 promotes human glioblastoma invasion through activation of PI3K/Akt pathway.

Excessive expression of Cluster of Differentiation 47 (CD47) is common in various malignancies. The aim of this study was to investigate whether CD47 promotes human glioblastoma invasion and its underlying mechanism of CD47 in promoting glioblastoma invasion. In this study we found that CD47 expression was stronger in glioblastoma patients and cells in comparison with normal controls. CD47 downregulation modulated by siRNA suppressed invasion in vitro. However, excessive CD47 expression modulated by transfection exerted opposite influence. In the meantime, excessive CD47 or knockdown CD47 expression had no effect on proliferation. Moreover, CD47 expression was related to AKT phosphorylation on cellular molecular level. AKT suppression with specific inhibitor impaired invasion of cells in which excessively expressed CD47, indicating that stimulation of PI3K/Akt pathway served as the downstream regulator of invasion triggered by CD47. These results suggest that CD47 might serve as a predictor of worse development as well as metastasis and brought about an innovative approach to treat glioblastoma.

1441 related Products with: CD47 promotes human glioblastoma invasion through activation of PI3K/Akt pathway.

Recombinant Human AKT-1 P Recombinant Human AKT-11 Recombinant Human AKT-11 Recombinant Human PI3K be Recombinant Human PI3K be Recombinant Human PI3K be Recombinant Human PI3K de Recombinant Human PI3K de Recombinant Human PI3K de Recombinant Human PI3K ga Recombinant Human PI3K ga Recombinant Human PI3K ga

Related Pathways

paperclip

#29308321   // Save this To Up

Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells.

Tumor initiating cells or cancer stem cells (CSCs) play an important role in the initiation, development, metastasis, and recurrence of tumors. However, traditional therapies have limited effects against CSCs and targeting these cells is crucial when developing new therapeutic strategies against cancer. One potentially targetable factor is CD47, a member of the immunoglobulin superfamily. This protein acts as an anti-phagocytic "don't eat me" signal and is often found expressed by cancer cells, particularly CSCs. CD47 functions by activating signal regulatory protein-α (SIRP-α) expressed on macrophages, preventing phagocytosis. However, the role of CD47 in glioma stem cells (GSCs) has been not been thoroughly investigated. Our study therefore examined the expression and function of this protein in glioma cells and GSCs. We found that CD47 was highly expressed on glioma cells, especially GSCs, and that expression associated with worse clinical outcomes. We also found that CD47+ glioma cells possessed stem/progenitor cell-like characteristics and knocking down CD47 expression resulted in a reduction in these characteristics. Treatment with anti-CD47 antibody led to increased phagocytosis of glioma cells and GSCs by macrophages. We next examined the effects of anti-CD47 antibody on glioma cells/GSCs in an immune competent mouse glioma model, revealing significant inhibition of tumor growth and prolonged survival times. Importantly, there were no apparent side effects in the animal model. In summary, we have shown that CD47 is a potentially safe and effective therapeutic target for glioma.

1409 related Products with: Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells.

FDA Standard Frozen Tissu FDA Standard Frozen Tissu Anti C Reactive Protein A Anti AGO2 Human, Monoclon Anti AGO2 Mouse, Monoclon Anti AGO2 Human, Monoclon Anti AGO2 Mouse, Monoclon anti HSV (II) gB IgG1 (mo anti HCMV IE pp65 IgG1 (m anti HCMV gB IgG1 (monocl Macrophage Colony Stimula Macrophage Colony Stimula

Related Pathways

  •  
  • No related Items
paperclip

#29308308   // Save this To Up

CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.

Here, we report on a novel bispecific antibody-derivative, designated RTX-CD47, with unique capacity for CD20-directed inhibition of CD47-SIRPα "don't eat me" signaling. RTX-CD47 comprises a CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv. Single agent treatment with RTX-CD47 triggered significant phagocytic removal of CD20pos/CD47pos malignant B-cells, but not of CD20neg/CD47pos cells, and required no pro-phagocytic FcR-mediated signaling. Importantly, treatment with RTX-CD47 synergistically enhanced the phagocytic elimination of primary malignant B cells by autologous phagocytic effector cells as induced by therapeutic anticancer antibodies daratumumab (anti-CD38), alemtuzumab (anti-CD52) and obinutuzumab (anti-CD20). In conclusion, RTX-CD47 blocks CD47 "don't eat me" signaling by cancer cells in a CD20-directed manner with essentially no activity towards CD20neg/CD47pos cells and enhances the activity of therapeutic anticancer antibodies directed to B-cell malignancies.

2683 related Products with: CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.

Interleukin-34 IL34 (N-t Th1 Th2 Th17 (Human) Anti Th1 Th2 Th17 (Human) Anti Antibody cross reactivity Interleukin-34 IL34 anti TCP-1 theta antibody Sour 2’-(Acetylthio)ethyl 2, (R,R)-N-(2-Amino-1,2-diph 5-Amino-3-(1-naphthyl)-4- 1-[(2S)-Amino-1-oxo-3-phe Arsenic Trichloride AsCl3 2-{N2-[N6-(4-Azido-2,3,5,

Related Pathways

  •  
  • No related Items
paperclip

#29296731   // Save this To Up

Human and murine splenic neutrophils are potent phagocytes of IgG-opsonized red blood cells.

Red blood cell (RBC) clearance is known to occur primarily in the spleen, and is presumed to be executed by red pulp macrophages. Erythrophagocytosis in the spleen takes place as part of the homeostatic turnover of RBCs to remove old RBCs. It can be strongly promoted by immunoglobulin G (IgG) opsonization of RBCs, a condition that can occur as a consequence of autoantibody or alloantibody formation. The purpose of our study was to investigate which phagocytes are involved in IgG-mediated RBC clearance in the human spleen. We developed a highly specific in vitro assay to monitor RBC phagocytosis in total human splenocytes. Surprisingly, we have found that whereas homeostatic clearance of RBCs is primarily a task for splenic macrophages, neutrophils and, to a lesser extent, also monocytes can be a major factor in clearance of IgG-opsonized RBCs. Erythrophagocytosis by neutrophils is strongly dependent on the degree of opsonization of the RBCs. Additionally, the process is enhanced after blocking the "do not eat me" signal CD47 on the opsonized RBCs, which binds signal regulatory protein α, a myeloid inhibitory receptor that restricts phagocytosis. Moreover, RBCs isolated from autoimmune hemolytic anemia patients, opsonized by auto-IgGs, were shown to be readily phagocytosed by neutrophils. Finally, priming of neutrophils by inflammatory mediators such as tumor necrosis factor α and lipopolysaccharide further increases the magnitude of erythrophagocytosis. Collectively, our data suggest that neutrophils contribute significantly to the phagocytosis of antibody-opsonized RBCs, especially under inflammatory conditions. This indicates a hereto unanticipated contribution of neutrophils in RBC phagocytosis, especially under pathological conditions such as alloimmunization or autoimmunization.

1473 related Products with: Human and murine splenic neutrophils are potent phagocytes of IgG-opsonized red blood cells.

Human Red Blood Cells Uni Rabbit Anti-Human Red Blo Human Cord Blood CD34+ Ce Chicken Red Blood Cells, Chicken Red Blood Cells, Chicken Red Blood Cells, Guinea Pig Red Blood Cell Guinea Pig Red Blood Cell Guinea Pig Red Blood Cell Guinea Pig Red Blood Cell Turkey Red Blood Cells 5% Turkey Red Blood Cells 5%

Related Pathways

paperclip

#29296529   // Save this To Up

The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma.

Diffuse malignant mesothelioma (DMM) is one of the prognostically most discouraging cancers with median survivals of only 12-22 months. Due to its insidious onset and delayed detection, DMM is often at an advanced stage at diagnosis and is considered incurable. Combined chemo- and radiotherapy followed by surgery only marginally affect outcome at the cost of significant morbidity. Because of the long time period between exposure to asbestos and disease onset, the incidence of DMM is still rising and predicted to peak around 2020. Novel markers for the reliable diagnosis of DMM in body cavity effusion specimens as well as more effective, targeted therapies are urgently needed. Here, we show that the "don't eat me" signalling molecule CD47, which inhibits phagocytosis by binding to signal regulatory protein α on macrophages, is overexpressed in DMM cells. A two-marker panel of high CD47 expression and BRCA1-associated protein 1 (BAP-1) deficiency had a sensitivity of 78% and specificity of 100% in discriminating DMM tumour cells from reactive mesothelial cells in effusions, which is superior to the currently used four-marker combination of BAP-1, glucose transporter type 1, epithelial membrane antigen and desmin. In addition, blocking CD47 inhibited growth and promoted phagocytosis of DMM cell lines by macrophages in vitro. Furthermore, DMM tumours in surgical specimens from patients as well as in a mouse DMM model expressed high levels of CD47 and were heavily infiltrated by macrophages. Our study demonstrates that CD47 is an accurate novel diagnostic DMM biomarker and that blocking CD47 may represent a promising therapeutic strategy for DMM.

1584 related Products with: The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma.

Interleukin-34 IL34 (N-t MOUSE ANTI BOVINE ROTAVIR MOUSE ANTI BORRELIA BURGD NATIVE HUMAN PROLACTIN, P RABBIT ANTI GSK3 BETA (pS 10x ELISA WASH BUFFER, Pr 10X PHOSPHATE BUFFERED SA PERMANENT AQUEOUS MOUNTIN FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu

Related Pathways

  •  
  • No related Items
paperclip

#29288236   // Save this To Up

CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.

Patients with pancreatic ductal adenocarcinoma (PDAC) who undergo surgical resection and adjuvant chemotherapy have an expected survival of only two years due to disease recurrence, frequently in the liver. We investigated the role of liver macrophages in progression of PDAC micrometastases to identify adjuvant treatment strategies that could prolong survival.

2221 related Products with: CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.

Cultrex In Vitro Angiogen Endothelial Tube Formatio Pancreatic cancer tissue Pancreatic cancer tissue CA125, Ovarian Cancer An CA125, Ovarian Cancer An CA125, Ovarian Cancer An MOUSE ANTI BOVINE ROTAVIR anti CD16 monoclonal anti Astrovirus antibody, Mono Annexin V FITC Reagent Annexin V FITC Reagent100

Related Pathways